SRC and colorectal cancer: Indeed, we demonstrated that active kinase candidates are discovered from the deep phosphop- and pY proteomic data (Table 1) and that the Src family kinases, SRC, and YES1 are potential druggable targets in colorectal cancer resistant to Cetuximab as shown in Fig. 5b.